IBS (IBS) Fair Value & Analysis
Real Estate · Market cap 26.7M PLN
Fair value as of: Jun 26, 2026
From 7 valuation models · updated 6 days ago
Share price −8.0% over the past month.
Price vs Fair Value (12 months)
12‑month range 65.04 PLN – 88.27 PLN · fair‑value band 3.13 PLN – 28.87 PLN · the 68.80 PLN price screens above the 13.63 PLN fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
IBS (IBS) currently trades at 68.80 PLN, while our model-based Fair Value estimate is 13.63 PLN — implying the stock looks roughly 80.2% overvalued today. We read business quality at 41/100 (below-average quality), in the Real Estate sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, IBS generated revenue of 18.4M PLN at a net margin of -30.8%. Revenue declined 68.6% year over year. It earns a return on equity of -14.8%. Net debt stands at 57.1M PLN. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
IBS reported revenue of 18.4M PLN in FY2025 versus 3.8M PLN in FY2021, a compound +48.0%/yr. Reported net income was −5.7M PLN in FY2025.
Is IBS fairly valued? → Check now
Similar stocks
6 more Real Estate Services stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vingroup Joint Stock Company VIC | 196,000 VND | 52,975 VND | -73% |
| CBRE Group CBRE | $127.86 | $81.43 | -36% |
| 2423 2423 | HK$38.90 | HK$17.91 | -54% |
| 1972 1972 | HK$20.40 | HK$18.75 | -8% |
| 1209 1209 | HK$36.68 | HK$34.70 | -5% |
| Plaza S.A MALLPLAZA | 3,830 CLP | 5,905 CLP | +54% |
Explore undervalued stocks
More undervalued Real Estate stocks →
Frequently asked questions
Is IBS (IBS) undervalued?
What is the fair value of IBS?
What is the quality score of IBS?
What is the revenue of IBS (IBS)?
What is the net profit margin of IBS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.